Navigation Links
New Drug May Offer Hope to Some With Lung Cancer
Date:9/19/2009

Pemetrexed improves survival with advanced non-small-cell tumors, study finds,,

SATURDAY, Sept. 19 (HealthDay News) -- Maintenance therapy with the drug pemetrexed improves the survival of people with non-small-cell lung cancer whose disease has not progressed after chemotherapy, a new study has found.

Nearly 90 percent of all people who die from lung cancer have non-small-cell tumors. At the time the cancer is discovered, it's considered advanced about 40 percent of the time, according to background information in a news release from The Lancet, which is publishing the study. Chemotherapy reduces the tumors in just 40 percent of advanced cases, it said.

The phase 3 study included 663 people in 20 countries who had an advanced stage of the cancer but no disease progression after four cycles of platinum-based chemotherapy. They were randomly selected to be given pemetrexed or a placebo in 21-day cycles.

The cancers did not progress for 4.3 months, on average, in people in the pemetrexed group, compared with 2.6 months in the placebo group, the study found. People given pemetrexed survived an average of 13.4 months, compared with 10.6 months for those given the placebo.

That means that those in the pemetrexed group had a 50 percent reduction in the risk for disease progression or death and a 21 percent reduction in the risk of death only, the researchers said.

Drug-related toxic effects caused discontinuation of treatment in 5 percent of the pemetrexed group and 4 percent of the placebo group. No deaths were found to be related to pemetrexed, according to the study.

"Pemetrexed maintenance therapy is well tolerated and offers significantly improved progression-free and overall survival compared with placebo, making it a new treatment option for patients with advanced non-squamous, non-small-cell lung cancer who do not progress after initial induction therapy," Dr. Chandra Belani, of the Penn State Hershey Cancer Institute, and her colleagues concluded.

The study, which appears online and in an upcoming print issue of The Lancet, was released Sept. 19 to coincide with the European Cancer Organization meeting.

Dr. Thomas Stinchcombe of the Lineberger Comprehensive Cancer Center at the University of North Carolina, and Dr. Howard West, of the Swedish Cancer Institute in Seattle, wrote in an accompanying editorial that the use of pemetrexed as maintenance therapy "merits being considered as a strong option, reflected by the recent approval of pemetrexed in this setting by the European Medicines Agency and the U.S. Food and Drug Administration."

More information

The American Cancer Society has more about non-small-cell lung cancer.



-- Robert Preidt



SOURCE: The Lancet, news release, Sept. 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Health care incentive model offers collaborative approach
3. Eye-staining technique offers early detection for dry eye syndrome
4. Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Psoriasis Cure Now offers Back to School Resources for Parents of Children with Psoriasis
7. ADDAS Awareness Campaign Offers Resources and Education to Adults Living with AD/HD and Professionals Working With Them
8. Consumers Offer to Pay More to Satisfy Health Demands
9. Regence Offers InterM to Fill Gap for the Uninsured
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Experimental Antidepressants Offer Faster Relief
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug May Offer Hope to Some With Lung Cancer
(Date:2/8/2016)... ... , ... CURE Media Group , the nation’s leading digital and print ... Awards event , which will annually honor individuals making heroic contributions in the field ... MM Heroes Awards nomination process is officially open through February 17 for patients, ...
(Date:2/8/2016)... PA (PRWEB) , ... February 08, 2016 , ... ... expanded authorization with BASF Human Nutrition into the Food & Beverage ... BSI has been BASF’s channel partner throughout Canada and USA geographies east of ...
(Date:2/8/2016)... Houma, LA (PRWEB) , ... February 08, 2016 ... ... Louisiana from offices in Houma, LA, celebrates the beginning of a new charity ... raised to assist Court Appointed Special Advocates (CASA). In the belief that children ...
(Date:2/8/2016)... ... ... man who has struggled to quit smoking, a man who has struggled with hair loss ... to his problems – and he did. Now Nabat, a serial entrepreneur featured as the ... inventions to the world and better people's lives. His own experience with nicotine addiction led ...
(Date:2/8/2016)... ... ... If you are feeling that your clothes are a tad snug, the ... Center for Disease Control and Prevention (CDC), 34.9% of U.S. adult women are overweight. ... some of the leading causes of preventable death. February is heart health month ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... and HONG KONG , Feb. ... Simon Pedder , PhD, has joined Athenex as Vice President ... and Mr. Raymond Yeung , MSc, MBA has joined as ... Asia-Pacific, based in Hong Kong . ... management team that I have known for a while. Coupled ...
(Date:2/9/2016)... , Feb. 9, 2016  Bluestar Silicones will ... product line for long-term implant applications and announce ... Design & Manufacturing (MD&M) West Conference (Booth #1759), ... --> --> Available ... Biomedical LSRs offer outstanding physical properties enabling our ...
(Date:2/8/2016)... , Feb.8, 2016 Cardiac ... Summary GlobalData,s Medical Devices sector report, ... Assessment, 2015 " provides an overview of Cardiac ... report provides comprehensive information on the pipeline products ... stages of development. The report reviews major players ...
Breaking Medicine Technology: